Precision BioSciences, Inc.
(NASDAQ : DTIL)

( )
DTIL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 8.42%419.050.0%$8674.93m
BNTXBioNTech SE 17.80%414.440.0%$1709.63m
NVAXNovavax, Inc. 18.69%223.8179.8%$898.59m
SNSSSunesis Pharmaceuticals, Inc. -0.92%10.720.7%$749.37m
AMGNAmgen, Inc. -6.46%228.311.3%$524.03m
BIIBBiogen, Inc. 0.03%338.101.7%$451.97m
VRTXVertex Pharmaceuticals, Inc. -0.23%199.591.9%$424.11m
GILDGilead Sciences, Inc. -0.85%69.241.0%$409.81m
REGNRegeneron Pharmaceuticals, Inc. -0.95%580.952.7%$330.19m
ILMNIllumina, Inc. 1.24%504.603.5%$271.58m
NTLAIntellia Therapeutics, Inc. 5.87%146.942.3%$204.93m
SGENSeagen Inc. 3.17%163.215.8%$137.56m
CRSPCRISPR Therapeutics AG 2.63%124.610.6%$137.02m
TBIOTranslate Bio, Inc. 0.48%37.853.3%$134.82m
EXASEXACT Sciences Corp. 1.56%105.8318.1%$131.45m

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.